M. Joerger

Discipline

Psychologie (1)

Type de document

Articles (7) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Patients (7) Patients (7) thérapie (6) Treatment (6) Therapeutics (6) Human beings (5) dose (4) maladie (4) Use (4) maladie (4) taux (3) survie (3) Development (3) Chemotherapy (3) Survival (3) Chemotherapy (3) Cancer (3) cohorte (3) puits (2) toxicité (2) norme (2) sécurité (2) biomarqueur (2) procès (2) cancer (2) Cancer (2) Area (2) Inhibitors (2) Area (2) Ci (Chinese poetry) (2)

Documents écrit par M. Joerger (7) | parle de M. Joerger (0)

SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
A. Digklia et al.
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
M. Joerger et al.
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
E. Schmulenson et al.
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
M. Joerger et al. (27 avr. 2022)
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
M.T. Purde et al.
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
S. Hamzic et al. (16 nov. 2020)
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
M. Fässler et al. (20 févr. 2019)